Enzo Biochem, Inc.
ENZ
$0.464
-$0.015-3.13%
| 10/31/2024 | 07/31/2024 | 04/30/2024 | 01/31/2024 | 10/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -20.41% | -16.00% | 7.17% | 13.83% | 9.90% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -20.41% | -16.00% | 7.17% | 13.83% | 9.90% |
| Cost of Revenue | -9.61% | -25.94% | -4.18% | -6.22% | -5.19% |
| Gross Profit | -34.01% | 2.38% | 24.06% | 45.76% | 37.43% |
| SG&A Expenses | -33.93% | -42.38% | -50.64% | -7.74% | 25.42% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -25.95% | -36.98% | -36.45% | -10.95% | 13.21% |
| Operating Income | 33.86% | 63.04% | 75.54% | 51.93% | -18.30% |
| Income Before Tax | 45.89% | 87.07% | 73.02% | 70.16% | -6.00% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 45.89% | 87.07% | 73.02% | 70.16% | -6.00% |
| Earnings from Discontinued Operations | 67.59% | -118.45% | 87.81% | 73.92% | 82.18% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 48.97% | -123.30% | 80.11% | 72.96% | 37.79% |
| EBIT | 33.86% | 63.04% | 75.54% | 51.93% | -18.30% |
| EBITDA | 36.55% | 65.68% | 77.86% | 51.06% | -36.03% |
| EPS Basic | 50.99% | -122.32% | 80.81% | 73.91% | 39.62% |
| Normalized Basic EPS | 48.09% | 87.95% | 73.97% | 71.16% | -2.91% |
| EPS Diluted | 46.89% | -122.34% | 80.81% | 73.91% | 39.65% |
| Normalized Diluted EPS | 48.09% | 87.95% | 73.97% | 71.16% | -2.91% |
| Average Basic Shares Outstanding | 4.10% | 3.54% | 3.71% | 3.61% | 3.00% |
| Average Diluted Shares Outstanding | 4.10% | 3.54% | 3.71% | 3.61% | 3.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
